CardioDx Wins Medicare OK of Molecular Test for Heart Disease
August 8, 2012
August 8, 2012 | CardioDx has spent three years marketing a new genetic test that can tell when a patient’s chest pain is a sign of serious heart disease. It has a long way to go before becoming part of mainstream medicine, but now the company has taken a big step ahead by persuading Medicare that its test is worth the money. The company is announcing today that Palmetto GBA, the national contractor for Medicare, has agreed to reimburse the company for its Corus CAD test. Xconomy
